These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2248131)

  • 1. The DMD gene promoter: a potential role in gene therapy.
    Ray PN; Klamut HJ; Worton RG
    Adv Exp Med Biol; 1990; 280():107-11; discussion 111-2. PubMed ID: 2248131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene.
    Klamut HJ; Bosnoyan-Collins LO; Worton RG; Ray PN; Davis HL
    Hum Mol Genet; 1996 Oct; 5(10):1599-606. PubMed ID: 8894694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy prospects for Duchenne muscular dystrophy.
    Clemens PR; Caskey CT
    Eur Neurol; 1994; 34(4):181-5. PubMed ID: 8082675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the MDA Gene Therapy Conference, Tucson, Arizona, September 27-28, 1991.
    Rossiter BJ; Stirpe NS; Caskey CT
    Neurology; 1992 Jul; 42(7):1413-8. PubMed ID: 1620357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for muscular dystrophies: current status and future prospects.
    Takeda S; Miyagoe-Suzuki Y
    BioDrugs; 2001; 15(10):635-44. PubMed ID: 11604045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell and gene therapy in Duchenne muscular dystrophy.
    Morgan JE
    Hum Gene Ther; 1994 Feb; 5(2):165-73. PubMed ID: 7514447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy.
    Burton EA; Tinsley JM; Holzfeind PJ; Rodrigues NR; Davies KE
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14025-30. PubMed ID: 10570192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in genome editing technologies for treating muscular dystrophy.].
    Makita Y; Hozumi H; Hotta A
    Clin Calcium; 2017; 27(3):391-399. PubMed ID: 28232654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple products of the Duchenne muscular dystrophy gene.
    Yaffe D; Makover A; Lederfein D; Rapaport D; Bar S; Barnea E; Nudel U
    Symp Soc Exp Biol; 1992; 46():179-88. PubMed ID: 1341034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel first exon in the human dystrophin gene and of a new promoter located more than 500 kb upstream of the nearest known promoter.
    Nishio H; Takeshima Y; Narita N; Yanagawa H; Suzuki Y; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M
    J Clin Invest; 1994 Sep; 94(3):1037-42. PubMed ID: 8083345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of DMD gene deletions in Thai children patients.
    Kamolsilp M; Paditaporn R; Noonai A; Wasant P
    Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():172-4. PubMed ID: 8629100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A housekeeping type promoter, located in the 3' region of the Duchenne muscular dystrophy gene, controls the expression of Dp71, a major product of the gene.
    Lederfein D; Yaffe D; Nudel U
    Hum Mol Genet; 1993 Nov; 2(11):1883-8. PubMed ID: 8281151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
    Rodrigues M; Yokota T
    Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Wellcome lecture, 1988. Muscular dystrophy: a time of hope.
    Kunkel LM
    Proc R Soc Lond B Biol Sci; 1989 Jun; 237(1286):1-9. PubMed ID: 2569197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstruction of the 2.4 Mb human DMD-gene by homologous YAC recombination.
    Den Dunnen JT; Grootscholten PM; Dauwerse JG; Walker AP; Monaco AP; Butler R; Anand R; Coffey AJ; Bentley DR; Steensma HY
    Hum Mol Genet; 1992 Apr; 1(1):19-28. PubMed ID: 1301131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the human Dp 71 (apo-dystrophin-1) gene from a 760-kb DMD-YAC transferred to mouse cells.
    Heikoop JC; Hogervorst FB; Meershoek EJ; Grootscholten PM; den Dunnen JT; van Ommen GJ
    Eur J Hum Genet; 1995; 3(3):168-79. PubMed ID: 7583042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy.
    Araki E; Nakamura K; Nakao K; Kameya S; Kobayashi O; Nonaka I; Kobayashi T; Katsuki M
    Biochem Biophys Res Commun; 1997 Sep; 238(2):492-7. PubMed ID: 9299538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular therapy of muscular dystrophy].
    Takeda S
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1267-9. PubMed ID: 11464475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy.
    Wells DJ; Wells KE; Asante EA; Turner G; Sunada Y; Campbell KP; Walsh FS; Dickson G
    Hum Mol Genet; 1995 Aug; 4(8):1245-50. PubMed ID: 7581360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell therapies to treat muscular dystrophy: progress to date.
    Meregalli M; Farini A; Parolini D; Maciotta S; Torrente Y
    BioDrugs; 2010 Aug; 24(4):237-47. PubMed ID: 20623990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.